Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02013167
Registration number
NCT02013167
Ethics application status
Date submitted
3/12/2013
Date registered
17/12/2013
Date last updated
5/03/2024
Titles & IDs
Public title
Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
Query!
Scientific title
A Phase 3, Randomized, Open Label Study Investigating the Efficacy of the BiTE Antibody Blinatumomab Versus Standard of Care Chemotherapy in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) (TOWER Study)
Query!
Secondary ID [1]
0
0
2013-000536-10
Query!
Secondary ID [2]
0
0
00103311
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Leukaemia - Acute leukaemia
Query!
Cancer
0
0
0
0
Query!
Leukaemia - Chronic leukaemia
Query!
Cancer
0
0
0
0
Query!
Children's - Leukaemia & Lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Blinatumomab
Treatment: Drugs - Standard of Care Chemotherapy
Experimental: Blinatumomab - Participants received blinatumomab by continuous intravenous infusion (CIVI) over 4 weeks followed by a 2 week treatment-free interval for 2 induction cycles. Participants who achieved a bone marrow response, complete remission, or complete remission with partial or incomplete hematologic recovery (CR/CRh*/CRi) within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of blinatumomab.
Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive blinatumomab for an additional 12 months (4 cycles), where 1 cycle consisted of 4 weeks of CIVI followed by an 8-week treatment-free period.
The initial dose of blinatumomab was 9 µg/day for the first 7 days of treatment, increased to 28 µg/day starting on day 8 through day 29 and for all subsequent cycles.
Active Comparator: Standard of Care Chemotherapy - Participants received one of four prespecified, investigator-chosen chemotherapy regimens for 2 induction cycles. Participants who achieved a bone marrow response, CR/CRh*/CRi within 2 induction cycles of treatment could receive up to 3 additional consolidation cycles of SOC chemotherapy.
Participants who received 2 induction and up to 3 consolidation cycles of therapy and continued to have a bone marrow response or CR/CRh*/CRi could continue to receive SOC therapy for an additional 12 months.
Treatment: Drugs: Blinatumomab
Blinatumomab is administered as a continuous intravenous infusion (CIV).
Treatment: Drugs: Standard of Care Chemotherapy
FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 & 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients > 60 years: Idarubicin 5 mg/m² day 1 & 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5
HiDAC (high-dose cytarabine arabinoside) - based regimen =1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents
High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.
Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival
Query!
Assessment method [1]
0
0
Overall survival (OS) was calculated from time of randomization until death due to any cause. Participants still alive were censored at the date they were last known to be alive.
Query!
Timepoint [1]
0
0
From randomization until the data cut-off date of 04 January 2016; median observation time was 11.8 months in the SOC group and 11.7 months in the blinatumomab group.
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Complete Remission Within 12 Weeks of Treatment Initiation
Query!
Assessment method [1]
0
0
Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts.
Complete Remission (CR) was defined as having = 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets > 100,000/µl, and absolute neutrophil count (ANC) > 1,000/µl. CR must have occurred within 12 weeks of the first dose of therapy.
Query!
Timepoint [1]
0
0
12 weeks
Query!
Secondary outcome [2]
0
0
Percentage of Participants With Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi) Within 12 Weeks of Treatment Initiation
Query!
Assessment method [2]
0
0
Participants were evaluated for efficacy at the end of each treatment cycle via a central bone marrow aspiration and local peripheral blood counts.
Complete remission was defined as having = 5% blasts in the bone marrow, no evidence of disease, and full recovery of peripheral blood counts: platelets > 100,000/µl, and ANC > 1,000/µl.
Complete Remission with partial hematological recovery (CRh*) was defined as = 5% blasts in the bone marrow, no evidence of disease and partial recovery of peripheral blood counts: platelets > 50,000/µl, and ANC > 500/µl.
Complete remission with incomplete hematological recovery (CRi) was defined as = 5% blasts in the bone marrow, no evidence of disease and incomplete recovery of peripheral blood counts: platelets > 100,000/µl or ANC > 1000 (but not both).
Query!
Timepoint [2]
0
0
12 weeks
Query!
Secondary outcome [3]
0
0
Event Free Survival (EFS)
Query!
Assessment method [3]
0
0
Event free survival was defined as the time from randomization until a documented relapse after achieving CR/CRh*/CRi or death, whichever occurred first. Participants who failed to achieve a CR/CRh*/CRi within 12 weeks of treatment initiation were considered as non-responders and assigned an EFS duration of 1 day. Participants still alive and relapse-free were censored on their last disease assessment date.
A relapse event was any one of the following:
Hematological relapse: proportion of blasts in bone marrow >5% or blasts in peripheral blood after documented CR or CRh* or CRi
Progressive disease: An increase from baseline of at least 25% of bone marrow blasts or an absolute increase of at least 5,000 cells/µL in the number of circulating leukemia cells
Extramedullary relapse: extramedullary lesion that is new or increased by 50% from nadir as assessed by Cheson criteria.
The Kaplan-Meier estimate of EFS at 6 months is reported.
Query!
Timepoint [3]
0
0
6 months
Query!
Secondary outcome [4]
0
0
Duration of Complete Remission
Query!
Assessment method [4]
0
0
Duration of complete remission, calculated only for participants who achieved a CR, was calculated from the date a CR was first achieved until the earliest date of a disease assessment indicating a relapse event or death, whichever occurred first. Participants who did not have a relapse event were censored on their last disease assessment date.
Query!
Timepoint [4]
0
0
Up to the data cut-off date of 04 January 2016; median observation time was 10.8 months in the SOC group and 7.0 months in the blinatumomab group.
Query!
Secondary outcome [5]
0
0
Duration of Complete Remission/Complete Remission With Partial Hematological Recovery/Complete Remission With Incomplete Hematological Recovery (CR/CRh*/CRi)
Query!
Assessment method [5]
0
0
Duration of CR/CRh*/CRi, calculated only for participants who achieved a CR/CRh*/CRi, was calculated from the date a CR/CRh*/CRi was first achieved until the earliest date of a disease assessment indicating a relapse event or death, whichever occurred first. Participants who did not have a relapse event were censored on their last disease assessment date.
Query!
Timepoint [5]
0
0
Up to the data cut-off date of 04 January 2016; median observation time was 10.8 months in the SOC group and 7.2 months in the blinatumomab group.
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Minimal Residual Disease (MRD) Within 12 Weeks of Treatment Initiation
Query!
Assessment method [6]
0
0
Bone marrow samples were evaluated for MRD remission by a central laboratory. MRD remission was defined as the occurrence of an MRD level below 10^-4 measured by quantitative reverse transcription polymerase chain reaction (PCR) or flow cytometry.
Query!
Timepoint [6]
0
0
12 weeks
Query!
Secondary outcome [7]
0
0
Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Up to the data cut-off date of 04 January 2016; maximum time on study was 23 months.
Query!
Secondary outcome [8]
0
0
Number of Participants With Adverse Events
Query!
Assessment method [8]
0
0
Adverse events (AEs) were graded for severity according to the CTCAE version 4.0, where Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living.
Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.
Grade 4: Life-threatening consequences; urgent intervention indicated. Grade 5: Death related to AE. Treatment-related adverse events (TRAEs) were those assessed by the investigator as possibly related to blinatumomab based on response to the question: Is there a reasonable possibility that the event may have been caused by blinatumomab or other protocol-specified therapies/procedures?
Query!
Timepoint [8]
0
0
From first dose of protocol-specified therapy until 30 days after the last dose, up to the data cut-off date of 04 January 2016; median duration of treatment was 5 days in the SOC group and 70 days in the blinatumomab group.
Query!
Secondary outcome [9]
0
0
100-Day Mortality After Allogeneic Hematopoietic Stem Cell Transplant
Query!
Assessment method [9]
0
0
The analysis of 100-day mortality after allogeneic HSCT was assessed for participants who achieved a best response of CR/CRh*CTi within 12 weeks of treatment initiation, who received an allogeneic HSCT and did not receive any additional anticancer treatment before the transplant. 100-day mortality after allogeneic HSCT was calculated relative to the date of allogeneic HSCT.
The 100-day mortality rate after allogeneic HSCT was defined as the percentage of participants having died up to 100 days after allogeneic HSCT estimated using the estimated time to death in percent calculated by Kaplan-Meier methods. Participants alive were censored on the last documented visit date or the date of the last phone contact when the patient was last known to have been alive.
Query!
Timepoint [9]
0
0
100 days, from the date of allogeneic HSCT until the data cut-off date of 04 January 2016
Query!
Secondary outcome [10]
0
0
Number of Participants With Anti-blinatumomab Antibodies
Query!
Assessment method [10]
0
0
Anti-blinatumomab binding antibodies were evaluated using a validated electrochemiluminescence (ECL)-based assay (binding assay). Samples positive for binding were analyzed using a cell-based bioassay to determine if the detected antibodies had neutralizing properties (neutralizing assay).
Query!
Timepoint [10]
0
0
Samples were collected on day 29 at the end of cycle 2 and 30 days after the last dose of blinatumomab (median duration of treatment was 70 days).
Query!
Secondary outcome [11]
0
0
Time to a 10-point Decrease From Baseline in Global Health Status and Quality of Life or Death
Query!
Assessment method [11]
0
0
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) is a 30-item questionnaire that assesses the health related quality of life of cancer patients. The EORTC QLQ-C30 consists of a global health status/quality of life (QoL) scale, 5 functional scales, 3 symptom scales, and 6 single items.
The global health/QoL scale consists of 2 questions that ask participants to rate their overall health and overall quality of life durig the past week on a scale from 1 (very poor) to 7 (excellent). The scale score was derived as the sum of each score and transformed to a scale from 0 to 100 where higher scores represent a high QoL.
Time to a =10-point decrease from baseline GHS/QoL or death, whichever came first, was calculated from baseline. Participants still alive and without a 10-point decrease in GHS/QoL EORTC QLQ-C30 were censored on their last EORTC QLQ-C30 assessment date.
Query!
Timepoint [11]
0
0
From randomization until the data cut-off date of 04 January 2016; EORTC QLQ-C30 was assessed on day 1, 8, 15, and 29 during cycle 1; days 1, 15, and 29 in cycle 2 and each consolidation cycle, and 30-days following the last dose of drug treatment.
Query!
Eligibility
Key inclusion criteria
- Subjects with Philadelphia negative B-precursor ALL, with any of the following:
- refractory to primary induction therapy or refractory to salvage therapy,
- in untreated first relapse with first remission duration <12 months
- in untreated second or greater relapse
- relapse at any time after allogeneic HSCT
- Subject has received intensive combination chemotherapy for the treatment of ALL for
initial treatment or subsequent salvage therapy.
- Greater than 5% blasts in the bone marrow
- Eastern Cooperative Oncology Group (ECOG) performance status = 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
- Malignancy other than ALL within 5 years before blinatumomab treatment, except for
adequately treated selected cancers without evidence of disease
- Diagnosis of Burkitt's leukemia according to World Health Organization classification,
or human immunodeficiency virus (HIV), Hepatitis B or C, or other clinically
significant disorder
- Current relevant central nervous system (CNS) pathology or known or suspected CNS
involvement
- Isolated extramedullary disease
- Current autoimmune disease or history of autoimmune disease with potential CNS
involvement
- Autologous HSCT within 6 weeks or allogeneic HSCT within 12 weeks before blinatumomab
treatment, or eligibility for allogeneic HSCT at the time of enrollment
- Active acute grade 2 to 4 graft versus host disease (GvHD) according to Glucksberg et
al (1974) criteria that required systemic treatment to prevent or treat GvHD 2 weeks
before blinatumomab treatment
- Known exclusion criteria to investigator choice of SOC chemotherapy (per package
insert)
- Cancer chemotherapy or radiotherapy with 2 weeks, or immunotherapy (included CD19
therapy) within 4 weeks of protocol-specified therapy
- Abnormal laboratory values (alanine or aspartate transaminase [ALT or AST] or alkaline
phosphatase [ALP] = 5 × upper limit of normal [ULN]; total bilirubin or creatinine =
1.5 × ULN), or calculated creatinine clearance < 60 mL/min.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
3/01/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
14/03/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
405
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Research Site - St Leonards
Query!
Recruitment hospital [2]
0
0
Research Site - Herston
Query!
Recruitment hospital [3]
0
0
Research Site - Adelaide
Query!
Recruitment hospital [4]
0
0
Research Site - Parkville
Query!
Recruitment hospital [5]
0
0
Research Site - Prahran
Query!
Recruitment hospital [6]
0
0
Research Site - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [2]
0
0
4029 - Herston
Query!
Recruitment postcode(s) [3]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [4]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [5]
0
0
3181 - Prahran
Query!
Recruitment postcode(s) [6]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Georgia
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Massachusetts
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Minnesota
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Missouri
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
New York
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
North Carolina
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
South Carolina
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Tennessee
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Texas
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Wisconsin
Query!
Country [14]
0
0
Austria
Query!
State/province [14]
0
0
Salzburg
Query!
Country [15]
0
0
Austria
Query!
State/province [15]
0
0
Wels
Query!
Country [16]
0
0
Austria
Query!
State/province [16]
0
0
Wien
Query!
Country [17]
0
0
Belgium
Query!
State/province [17]
0
0
Antwerpen
Query!
Country [18]
0
0
Belgium
Query!
State/province [18]
0
0
Brugge
Query!
Country [19]
0
0
Belgium
Query!
State/province [19]
0
0
Bruxelles
Query!
Country [20]
0
0
Belgium
Query!
State/province [20]
0
0
Ghent
Query!
Country [21]
0
0
Belgium
Query!
State/province [21]
0
0
Leuven
Query!
Country [22]
0
0
Belgium
Query!
State/province [22]
0
0
Yvoir
Query!
Country [23]
0
0
Bulgaria
Query!
State/province [23]
0
0
Plovdiv
Query!
Country [24]
0
0
Bulgaria
Query!
State/province [24]
0
0
Sofia
Query!
Country [25]
0
0
Canada
Query!
State/province [25]
0
0
Ontario
Query!
Country [26]
0
0
Canada
Query!
State/province [26]
0
0
Quebec
Query!
Country [27]
0
0
Czechia
Query!
State/province [27]
0
0
Brno
Query!
Country [28]
0
0
Czechia
Query!
State/province [28]
0
0
Hradec Kralove
Query!
Country [29]
0
0
Czechia
Query!
State/province [29]
0
0
Praha 10
Query!
Country [30]
0
0
Czechia
Query!
State/province [30]
0
0
Praha 2
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Creteil Cedex
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Le Chesnay
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Nantes Cedex 1
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Paris Cedex 10
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Pessac Cedex
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Pierre-Benite
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Toulouse cedex 9
Query!
Country [38]
0
0
Germany
Query!
State/province [38]
0
0
Berlin
Query!
Country [39]
0
0
Germany
Query!
State/province [39]
0
0
Essen
Query!
Country [40]
0
0
Germany
Query!
State/province [40]
0
0
Frankfurt am Main
Query!
Country [41]
0
0
Germany
Query!
State/province [41]
0
0
Freiburg
Query!
Country [42]
0
0
Germany
Query!
State/province [42]
0
0
Heidelberg
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Kiel
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Köln
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Leipzig
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
München
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Münster
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Tübingen
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Ulm
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Würzburg
Query!
Country [51]
0
0
Greece
Query!
State/province [51]
0
0
Athens
Query!
Country [52]
0
0
Greece
Query!
State/province [52]
0
0
Ioannina
Query!
Country [53]
0
0
Greece
Query!
State/province [53]
0
0
Patra
Query!
Country [54]
0
0
Greece
Query!
State/province [54]
0
0
Thessaloniki
Query!
Country [55]
0
0
Ireland
Query!
State/province [55]
0
0
Dublin
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Haifa
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Jerusalem
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Petah Tikva
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Tel Aviv
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Tel Hashomer
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Bari
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Bergamo
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Bologna
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Firenze
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Napoli
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Novara
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Palermo
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Roma
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Torino
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Venezia
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Verona
Query!
Country [72]
0
0
Korea, Republic of
Query!
State/province [72]
0
0
Busan
Query!
Country [73]
0
0
Korea, Republic of
Query!
State/province [73]
0
0
Seoul
Query!
Country [74]
0
0
Mexico
Query!
State/province [74]
0
0
Distrito Federal
Query!
Country [75]
0
0
Mexico
Query!
State/province [75]
0
0
Nuevo León
Query!
Country [76]
0
0
Poland
Query!
State/province [76]
0
0
Lublin
Query!
Country [77]
0
0
Poland
Query!
State/province [77]
0
0
Warszawa
Query!
Country [78]
0
0
Poland
Query!
State/province [78]
0
0
Wroclaw
Query!
Country [79]
0
0
Russian Federation
Query!
State/province [79]
0
0
Moscow
Query!
Country [80]
0
0
Russian Federation
Query!
State/province [80]
0
0
Nizhny Novgorod
Query!
Country [81]
0
0
Russian Federation
Query!
State/province [81]
0
0
Petrozavodsk
Query!
Country [82]
0
0
Russian Federation
Query!
State/province [82]
0
0
Saratov
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Asturias
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
Castilla León
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Cataluña
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Comunidad Valenciana
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Madrid
Query!
Country [88]
0
0
Taiwan
Query!
State/province [88]
0
0
ChangHua
Query!
Country [89]
0
0
Taiwan
Query!
State/province [89]
0
0
Taichung
Query!
Country [90]
0
0
Taiwan
Query!
State/province [90]
0
0
Tainan
Query!
Country [91]
0
0
Taiwan
Query!
State/province [91]
0
0
Taipei
Query!
Country [92]
0
0
Turkey
Query!
State/province [92]
0
0
Adana
Query!
Country [93]
0
0
Turkey
Query!
State/province [93]
0
0
Ankara
Query!
Country [94]
0
0
Turkey
Query!
State/province [94]
0
0
Istanbul
Query!
Country [95]
0
0
Turkey
Query!
State/province [95]
0
0
Izmir
Query!
Country [96]
0
0
United Kingdom
Query!
State/province [96]
0
0
Bristol
Query!
Country [97]
0
0
United Kingdom
Query!
State/province [97]
0
0
London
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Oxford
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Sheffield
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Southampton
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Sutton
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective was to evaluate the effect of blinatumomab on overall survival when
compared to standard of care (SOC) chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02013167
Query!
Trial related presentations / publications
Delea TE, Amdahl J, Boyko D, Hagiwara M, Zimmerman ZF, Franklin JL, Cong Z, Hechmati G, Stein A. Cost-effectiveness of blinatumomab versus salvage chemotherapy in relapsed or refractory Philadelphia-chromosome-negative B-precursor acute lymphoblastic leukemia from a US payer perspective. J Med Econ. 2017 Sep;20(9):911-922. doi: 10.1080/13696998.2017.1344127. Epub 2017 Jul 11.
Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foa R, Bassan R, Arslan O, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Bruggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783.
Dombret H, Topp MS, Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H. Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2019 Sep;60(9):2214-2222. doi: 10.1080/10428194.2019.1576872. Epub 2019 Apr 5.
Kuchimanchi M, Zhu M, Clements JD, Doshi S. Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy. Br J Clin Pharmacol. 2019 Apr;85(4):807-817. doi: 10.1111/bcp.13864. Epub 2019 Feb 18.
Stein AS, Larson RA, Schuh AC, Stevenson W, Lech-Maranda E, Tran Q, Zimmerman Z, Kormany W, Topp MS. Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv. 2018 Jul 10;2(13):1522-1531. doi: 10.1182/bloodadvances.2018019034.
Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, Franklin J, Tran Q, Cong Z, Schuh AC. Health-related quality of life in adults with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood. 2018 Jun 28;131(26):2906-2914. doi: 10.1182/blood-2017-09-804658. Epub 2018 May 8.
Kantarjian HM, Zugmaier G, Bruggemann M, Wood BL, Horst HA, Zeng Y, Martinelli G. Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia. Cancers (Basel). 2021 Nov 9;13(22):5607. doi: 10.3390/cancers13225607.
Horst HA, Zugmaier G, Martinelli G, Mergen N, Velasco K, Zaman F, Kantarjian H. CD19-negative relapse in adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia following treatment with blinatumomab-a post hoc analysis. Am J Hematol. 2023 Aug;98(8):E222-E225. doi: 10.1002/ajh.26988. Epub 2023 Jun 22. No abstract available.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02013167
Download to PDF